NCIMB

Executive Summary

NCIMB is a UK-based microbiology services company with a 70+ year history, specializing in microbial strain preservation, identification, testing, and storage. Leveraging an extensive culture collection, it supports industrial and research applications across sectors such as pharmaceuticals, food, and agriculture. As a private entity, NCIMB is not publicly traded but plays a critical role in the microbiome and synthetic biology value chain by providing essential services to companies developing microbial products. Its established reputation and long-term client relationships position it as a stable, niche player with potential for steady growth as demand for outsourced microbiology services increases. However, the company's lack of disclosed revenue, funding, or recent growth metrics limits visibility into near-term performance. Overall, NCIMB represents a low-risk, low-growth opportunity in the private markets, with value derived from its proprietary culture collection and service reliability.

Upcoming Catalysts (preview)

• Q3 2026Expansion of culture collection through new acquisitions or partnerships60% success
• Q4 2026Strategic partnership with a major pharmaceutical company for strain banking services50% success
• Q1 2027Launch of a new service line (e.g., microbiome analysis or synthetic biology support)40% success